OnKure Therapeutics, Inc. (OKUR)

OnKure Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022
Cash & Equivalents	96.66	110.76	29.88	11.54
Cash & Short-Term Investments	96.66	110.76	29.88	11.54
Cash Growth	402.19%	270.74%	158.82%	-
Prepaid Expenses	1.51	2.24	3.89	2.08
Total Current Assets	98.17	113	33.77	13.62
Property, Plant & Equipment	1.6	1.8	1.91	2.05
Other Long-Term Assets	0.11	0.11	0.06	0.33
Total Assets	99.88	114.91	35.73	16
Accounts Payable	2.34	2.97	3.42	2.52
Accrued Expenses	5.9	7.03	3.66	2.87
Current Portion of Leases	0.55	0.54	0.21	0.15
Total Current Liabilities	8.79	10.53	7.29	5.54
Long-Term Leases	0.41	0.55	0.47	0.49
Total Liabilities	9.23	11.08	7.75	6.03
Common Stock	0	0	-	0
Additional Paid-In Capital	261.3	258.55	0.21	2.66
Retained Earnings	-170.65	-154.72	-102.05	-57.07
Total Common Equity	90.65	103.83	-101.84	-54.42
Shareholders' Equity	90.65	103.83	27.98	9.97
Total Liabilities & Equity	99.88	114.91	35.73	16
Total Debt	0.96	1.09	0.67	0.64
Net Cash (Debt)	95.71	109.68	29.2	10.91
Net Cash Growth	413.88%	275.58%	167.76%	-
Net Cash Per Share	14.23	31.82	102.89	-
Filing Date Shares Outstanding	13.44	13.44	13.34	-
Total Common Shares Outstanding	13.44	13.35	13.34	-
Working Capital	89.39	102.47	26.48	8.08
Book Value Per Share	6.74	7.78	-7.63	-
Tangible Book Value	90.65	103.83	-101.84	-54.42
Tangible Book Value Per Share	6.74	7.78	-7.63	-
Machinery	-	1.05	1.01	0.85
Leasehold Improvements	-	1.09	1.09	1

Updated Mar 10, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q